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South African pharmaceutical industry is more likely to be in 
clinical trials than in basic R&D.
However, good prospects exist for increased clinical trials 
activity. There are factors that may attract this, such as well-
established credentials in medical research, high-quality 
personnel, relatively good infrastructure,8 access to a larger 
African market, a relatively drug-naïve population, and a high 
burden of disease.
Policies should therefore be directed towards this end, 
and could include application of new R&D tax incentives, 
co-financing, access to infrastructure, a proactive regulatory 
environment, and better application of immigration regulations 
as a means toward ‘brain gain’ of highly skilled personnel.
This work is supported by funding provided to the Centre for 
Science, Technology and Innovation Indicators (CeSTII), by the 
Department of Science and Technology and the Human Sciences 
Research Council. The authors acknowledge the assistance of 
Natalie Vlotman and Maalikah van der Schyff in data gathering 
and analysis.
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Incidence of nevirapine-associated hepatitis in an antenatal 
clinic
V Black, H Rees 
In April 2004 the South African Department of Health initiated 
comprehensive care for HIV-infected people that included 
the use of antiretroviral therapy (ART) in the public health 
sector.  The first-line regimen consists of two nucleoside 
reverse transcriptase inhibitors, lamivudine and stavudine, 
together with a non-nucleoside reverse transcriptase inhibitor, 
either efavirenz or nevirapine.1 As efavirenz is thought to be a 
teratogen and is classified as a Food and Drug Administration 
(FDA) category D drug, nevirapine is the preferred agent for 
use in pregnant women, for women planning a pregnancy and 
for women at risk of becoming pregnant. Nevirapine is a highly 
effective antiretroviral (ARV) agent when used in combination 
with other appropriate ARVs.2 Nevirapine has two principal 
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Objective. To describe the incidence, clinical presentation 
and management of nevirapine-associated hepatitis among 
antiretroviral-naïve pregnant women treated with nevirapine- 
based antiretroviral therapy at a dedicated antenatal 
antiretroviral clinic.
Methods. Retrospective analysis of pregnant women initiated 
on nevirapine-based highly active antiretroviral therapy at 
a dedicated antenatal antiretroviral clinic between July 2004 
and December 2006.
Results. Three hundred and ninety women were included in 
the analysis. Median age was 29 (interquartile range (IQR) 
26 - 32) years and median pre-treatment CD4 cell counts was 
157 (IQR 104 - 193) cells/µl. Baseline alanine transaminase 
(ALT)  was elevated in 2.8% of women (11/390). After 
initiation of nevirapine-based ART 8% (31/390) experienced 
an ALT elevation. Three of these patients developed clinical 
hepatitis with jaundice (0.8%, 3/390). The mean and median 
time to clinical presentation was 5 weeks. Hepatitis resolved 
following discontinuation of ART. Non-nevirapine regimens 
were initiated following biochemical and symptomatic 
improvement; symptoms did not recur.
Conclusions.  Among pregnant women, nevirapine-containing 
ART has a favourable safety profile, with a low incidence of 
serious hepatic events.
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side-effects that are of particular concern to clinicians, which are 
Stevens-Johnson syndrome and hepatitis, both of which may be 
fatal.3,4 
In response to the large number of pregnant women requiring 
ART, a specialised antenatal ARV clinic was established at 
Johannesburg Hospital in July 2004. We describe the incidence 
and clinical presentation of nevirapine-associated hepatitis 
among pregnant women treated with nevirapine at this clinic, 
and discuss management of this condition.
Methods
Pregnant women who were initiated on nevirapine-containing 
ART regimens between July 2004 and December 2006 were 
included in this analysis. Once initiated on ART these women 
were followed up weekly for the first 4 weeks and then 2 - 4-
weekly until delivery. From October 2005 women were followed 
up to 10 weeks post partum. Alanine transaminase (ALT) levels 
were measured at baseline, at weeks 1 and 3 of ART treatment, 
and 2-weekly thereafter until 8 weeks of ART were completed. 
Demographic and clinical details for women attending the 
antenatal ARV clinic were entered into an Excel database. 
Variables collected included age, baseline clinical characteristics, 
pre-treatment and subsequent ALT levels and CD4 cell count. 
Descriptive and summary statistics were performed, with 
continuous variables expressed as medians and interquartile 
ranges (IQRs).
Approval for the study was granted by the Human Research 
Ethics Committee of the University of the Witwatersrand.  
Results
Three hundred and ninety women attending the antenatal ARV 
clinic received a nevirapine-based regimen and were eligible 
for analysis. The median age was 29 (IQR 26 - 32) years and the 
median pre-treatment CD4 cell counts were 157 (IQR 104 - 193) 
cells/µl. Baseline alanine aminotransferase (ALT) was elevated 
in 2.8% of women (11/390) after initiating ART.  One of these 
women had a further transaminase increase that did not require 
a change in management. 
After initiation of nevirapine-based ART, 31 of 390 patients 
(8%) experienced an ALT elevation. Twenty-eight patients 
(7.2%) had grade 1 (1.25 - 2.5 × ULN),5 2 patients (0.5%) had 
grade 2 (2.6 - 5.0 × upper limit of normal (ULN))5 and 1 patient 
(0.3%) had grade 4 (> 10.0 × ULN)5 elevation in ALT. Of these, 2 
patients with grade 1 ALT elevation and the patient with grade 
4 elevation developed clinical hepatitis, with jaundice (0.8%, 
3/390). Clinical characteristics of these 3 patients are presented 
in Table I. Serological markers for hepatitis A, B and C were 
negative and pre-treatment CD4 cell counts were below 200 
cells/µl for all 3 patients. Pre-treatment and first monitoring of 
ALT 1 - 3 weeks after initiating nevirapine were all normal. Two 
of the 3 patients had insidious onset of nevirapine-associated 
hepatitis with fever and nonspecific abdominal pain before 
jaundice. All cases occurred between 5 and 6 weeks. In all 3 
cases, hepatitis rapidly resolved following discontinuation of 
ART. Non-nevirapine regimens, substituting lopinavir/ritonavir 
for nevirapine, were initiated following biochemical and 
symptomatic improvement; symptoms did not recur. In 1 patient 
viral load was not suppressed on the new ART regimen, and 
after delivery she defaulted from follow-up. 
Nineteen women (4.9%) in the cohort were changed from 
nevirapine to either efavirenz or lopinavir/ritonavir-based 
ART within 5 weeks of initiating nevirapine-based ART, 5 due 
to development of a nevirapine rash, 13 due to initiation of TB 
therapy, and 1 due to suspected auto-immune hepatitis. 
Discussion
The Johannesburg Hospital antenatal ARV clinic has a low 
incidence of nevirapine hepatitis (0.8%). This may be due to 
a low threshold for nevirapine substitution in patients with 
a perceived risk of developing hepatitis, especially those on 
Table I. Characteristics of women who developed hepatitis
Variables Patient 1 Patient 2 Patient 3
Age (yrs) 26 29 31
Pre-treatment CD4 cell count (cells/µl) 172 11 191
Pre-treatment ALT (normal <40 IU/l) 16 29 21
Previous single-dose nevirapine for PMTCT Yes No No
Gestational age at initiation of ART (wks) 20 18 18 
Nevirapine skin rash No Yes No
Interval between initiating ART and hepatitis (wks) 5.4 5 5 
First clinical presentation Pyrexia, nonspecific pains Jaundice Pyrexia
Interval between discontinuing and re-introducing  
ART (wks) 2  6  2 
New regimen LPN/RTV LPV/RTV LPV/RTV
 Stavudine Stavudine Zidovudine
 Lamivudine Lamivudine Lamivudine
ALT = alanine transminase; PMTCT = prevention of mother-to-child transmission; ART = antiretroviral therapy; LPN/RTN = lopinavir/ritonavir.
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concurrent TB treatment, the low CD4 cell count of most 
women initiated on nevirapine therapy, the low number with 
an elevated pre-treatment ALT level and low reported alcohol 
and drug use among women attending the clinic. Other 
investigators6 have reported a low incidence of nevirapine 
toxicity in pregnant women. 
Nevirapine-associated hepatotoxicity with elevation of 
transaminases to more than 5 times the upper limit of normal 
(ULN) occurred in 10% (range 1.1 - 17%) of HIV-infected 
nevirapine-treated patients in 17 clinical trials that included 
patients with high CD4 cell counts.7 In these trials, overall rates 
of serious hepatic events and death were low (0.06 - 0.13%).7 
Clinical symptoms developed in 4.9% (3.2 - 8.9%) of patients.7 
One of these studies from South Africa3 reported an incidence 
of nevirapine hepatitis of 17%, with 2 fatalities due to fulminant 
hepatitis despite discontinuation of ART. Clinical predictors of 
nevirapine-associated hepatitis included elevated transaminases 
>2.5 times the ULN before initiating ART, viral hepatitis B or C 
infection, and being female with a CD4 cell count greater than 
250 cells/µl.8 Development of skin rash following initiation 
of nevirapine is associated with a >10-fold increased risk of 
hepatitis.7,9 Only 1 woman who developed hepatitis in this study 
had a known risk factor for hepatitis, transient rash 2 weeks after 
initiating nevirapine-based ART. 
 Nevirapine-associated hepatitis may have an insidious 
onset. Laboratory monitoring of ALT did not predict hepatitis 
in any of the 3 patients who developed hepatitis. A high index 
of suspicion is therefore needed in patients who present with 
nonspecific clinical symptoms shortly after starting nevirapine. 
Patients who develop rash following initiation of nevirapine-
based ART should be monitored and made aware of symptoms 
of hepatitis. In cases of nevirapine rash where close monitoring 
is not possible, nevirapine substitution should be considered. 
Options include substitution with a protease inhibitor in 
situations such as co-infection with tuberculosis in the first 
trimester of pregnancy, a nucleoside reverse transcriptase 
inhibitor (triple nucleoside regimen), or changing from 
nevirapine to efavirenz.  Efavirenz has been classified as a 
potential teratogen and should be avoided in early pregnancy.10 
Where lopinavir/ritonavir has not been tolerated the authors 
have used efavirenz in pregnant women beyond the first 
trimester after risk counselling.  No adverse outcomes were 
observed.  
A limitation of this study is that follow-up over time varied, 
and any late incidence of hepatitis may be under-reported. 
However, this may have a minimal effect on the study, as 
hepatic events usually occur within 6 weeks of initiating 
nevirapine-based therapy.7
It is important to note that severe adverse events following 
single drug administration of nevirapine to pregnant women 
as part of prevention of mother-to-child transmission (PMTCT) 
of HIV has not been reported.11-13 Programmes built around 
this regimen remain important for preventing HIV infection 
to newborns where more effective regimens have not yet been 
implemented.14
Conclusion
Nevirapine-based triple therapy in South Africa’s state sector 
is principally recommended for pregnant women or women 
at risk of pregnancy who do not have contraindications to 
nevirapine (background liver disease or a CD4 count >250 
cells/µl). Findings of this study suggest that in this study 
population nevirapine-containing ART has a favourable 
safety profile, with a low incidence of serious hepatic events. 
Laboratory monitoring did not predict hepatitis in any of the 3 
patients who developed hepatitis.
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